Last reviewed · How we verify
Collection of blood and bone marrow
Collection of blood and bone marrow is a Biologic drug developed by University Hospital, Clermont-Ferrand. It is currently in Phase 1 development.
At a glance
| Generic name | Collection of blood and bone marrow |
|---|---|
| Sponsor | University Hospital, Clermont-Ferrand |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (PHASE2)
- Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (PHASE1)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia (PHASE2)
- BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (PHASE2)
- A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) (PHASE2)
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Collection of blood and bone marrow CI brief — competitive landscape report
- Collection of blood and bone marrow updates RSS · CI watch RSS
- University Hospital, Clermont-Ferrand portfolio CI
Frequently asked questions about Collection of blood and bone marrow
What is Collection of blood and bone marrow?
Collection of blood and bone marrow is a Biologic drug developed by University Hospital, Clermont-Ferrand.
Who makes Collection of blood and bone marrow?
Collection of blood and bone marrow is developed by University Hospital, Clermont-Ferrand (see full University Hospital, Clermont-Ferrand pipeline at /company/university-hospital-clermont-ferrand).
What development phase is Collection of blood and bone marrow in?
Collection of blood and bone marrow is in Phase 1.